Keyphrases
CD34+ Cell Dose
100%
Angina
100%
2-year Outcome
100%
Refractory Angina
100%
High Dose
80%
Placebo
40%
CD34
40%
CD34+ Stem Cells
40%
Ischemic Myocardium
20%
Revascularization
20%
Perfusion
20%
Myocardial Infarction
20%
CD34+ Cells
20%
Number of Patients
20%
New Blood Vessel
20%
Quality of Life Assessment
20%
Randomized Placebo-controlled Trial
20%
Heart Failure Hospitalization
20%
Injection Technique
20%
Long-term Efficacy
20%
Acute Coronary Syndrome
20%
Placebo Groups
20%
Long-term Safety
20%
Optimal Medical Therapy
20%
Adverse Cardiac Events
20%
Testing Time
20%
Exercise Duration
20%
Blood Vessel Formation
20%
Coronary Heart
20%
Ischemic Zone
20%
24-month Follow-up
20%
Exercise Tolerance Test
20%
Intramyocardial Delivery
20%
No-option
20%
Medicine and Dentistry
Cell Therapy
100%
Angina pectoris
100%
Low Drug Dose
55%
Drug Megadose
44%
Placebo
44%
Stem Cell
22%
Exercise Tolerance
11%
Angiogenesis
11%
Myocardial Infarction
11%
Combination Therapy
11%
Revascularization
11%
Quality of Life Assessment
11%
Body Weight
11%
Controlled Clinical Trial
11%
Heart Muscle Ischemia
11%
Congestive Heart Failure
11%
Acute Coronary Syndrome
11%
Major Adverse Cardiac Event
11%
Immunology and Microbiology
CD34
100%
Low Drug Dose
71%
Drug Megadose
57%
Stem Cell
28%
Preclinical Study
14%
Perfusion
14%
Exercise Tolerance
14%
Body Weight
14%
Angiogenesis
14%
Revascularization
14%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Preclinical Study
25%
Controlled Clinical Trial
25%
Heart Infarction
25%
Congestive Heart Failure
25%
Heart Muscle Ischemia
25%
Acute Coronary Syndrome
25%
Major Adverse Cardiac Event
25%
Combination Therapy
25%